NCT04093076View on ClinicalTrials.gov

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

PHASE1CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions
Lassa Fever
Interventions
DRUG

INO-4500

INO-4500 will be administered ID on Day 0 and Week 4.

DEVICE

CELLECTRA™ 2000

EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.

DRUG

Placebo

Placebo will be administered ID on Day 0 and Week 4.

Trial Locations (1)

Unknown

Noguchi Memorial Institute for Medical Research, University of Ghana, Legon

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Inovio Pharmaceuticals

INDUSTRY